

Decision Explained

Medicine: venetoclax (brand name: Venclyxto®)

AbbVie Ltd

The Scottish Medicines Consortium (SMC) has assessed venetoclax for the treatment of a type of leukaemia called chronic lymphocytic leukaemia (CLL). It is used in combination with another cancer medicine called obinutuzumab to treat patients who have not yet had any other treatment for their CLL. This document summarises the SMC decision and what it means for patients.

What has SMC said?

After careful consideration, SMC has accepted venetoclax in combination with obinutuzumab for use in certain patients (restricted use). The restriction means that venetoclax in combination with obinutuzumab may be used in patients who:

- have not been previously treated for their CLL; and
- who do not have a del(17p)/TP53 mutation (a genetic change present in the cancer cells of 5-10% of patients with CLL); and
- who are fit enough to receive the chemo-immunotherapy FCR (fludarabine, cyclophosphamide and rituximab).

This SMC advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of venetoclax.

What does SMC's decision mean for patients?

If your healthcare professional thinks that venetoclax for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland



What is venetoclax used for?

Venetoclax is used for the treatment of CLL, which is a type of blood cancer. In CLL, a type of white blood cell called B cells become cancerous. SMC has accepted venetoclax in combination with obinutuzumab for treating adults with CLL who are: previously untreated, do not have a del(17p)/TP53 mutation in their cancer cells and who are fit enough to be treated with a type of chemotherapy called FCR.

How does venetoclax work?

Venetoclax works by blocking the actions of a protein called BCL-2. BCL-2 is produced in large amounts by cancerous white blood cells and helps them to survive and build up in the body. By

blocking BCL-2, venetoclax helps to reduce the number of cancer cells and slow the progression of the cancer.

How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of venetoclax by looking at the SMC Detailed Advice Document (SMC2427).


More information

The organisation below can provide more information and support for people with CLL and their families. SMC is not responsible for the content of any information provided by external organisations.

Leukaemia Care



https://www.leukaemiacare.org.uk



CLL Support




https://www.cllsupport.org.uk



Lymphoma Action



https://lymphoma-action.org.uk



You can find out more about venetoclax (Venclyxto®) in the Patient Leaflet by searching for the medicine name on the electronic medicines compendium (EMC) website.



https://www.medicines.org.uk/emc/

SMC No: SMC2427 Date advice published: 9 May 2022